News

Emmaus Unveils Co-payment Assistance Program for SCD Endari Patients

For eligible sickle cell disease (SCD) patients covered by commercial insurance, biopharmaceutical company Emmaus Life Sciences will offer financial assistance to those who need help covering their monthly Endari co-payments. Emmaus is the developer of Endari (L-glutamine oral powder, and called Xyndari in Europe). In the United…

Crizanlizumab Designated FDA Breakthrough Therapy for Potential in Vaso-occlusive Crisis Prevention

Crizanlizumab (SEG101), Novartis‘ investigational compound for sickle cell disease (SCD), received breakthrough therapy designation from the U.S. Food and Drug Administration for its potential to prevent vaso-occlusive crises (VOCs). The FDA designation was granted based on promising data from the company’s multicenter, randomized, double-blind, 52-week, Phase…